Literature DB >> 21884408

Minor antigens on transfused RBCs crossprime CD8 T cells but do not induce full effector function.

M Desmarets1, G Mylvaganam, E K Waller, C D Josephson, C Pack, A E Lukacher, J C Zimring.   

Abstract

HLA-matched bone marrow transplantation (BMT) is a cure for nonmalignant hematological disorders; however, rejection rates are high and correlate with the number of antecedent transfusions. Recently, using murine models, we reported that minor antigens (mHAs) in transfused leukoreduced red blood cell (RBC) or platelet units induce rejection of subsequent BMT. To study RBCs as an immunogen, we utilized transgenic donors that express a model mHA selectively on RBCs (HOD mouse). Transfusion of HOD blood did not induce BMT rejection of marrow that shared mHAs with the HOD RBCs. Similarly, no endogenous anti-HOD CD8(+) T-cell response was detected with antigen-specific tetramer reagents. Adoptively transferred OT-I T cells rapidly expanded after HOD blood transfusion; however, only a semi-effector phenotype was observed (tumor necrosis factor-α and interferon-γ secretion, but essentially no Granzyme B). After initial expansion, OT-I T cells contracted rapidly to very low levels. A similar trend was observed by in vivo CTL assay, with only transient lytic activity. Together, these data indicate that RBCs may not be the component of RBC units that induces BMT rejection, and suggest that contaminating platelets or leukocytes may be responsible. © 2011 The Authors Journal compilation
© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 21884408      PMCID: PMC4284100          DOI: 10.1111/j.1600-6143.2011.03730.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  35 in total

1.  Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.

Authors:  E Gluckman; M M Horowitz; R E Champlin; J M Hows; A Bacigalupo; J C Biggs; B M Camitta; R P Gale; E C Gordon-Smith; A M Marmont
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

2.  Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein.

Authors:  A E Lukacher; C S Wilson
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  The effect of prior blood transfusions on hemopoietic grafts from histoincompatible canine littermates.

Authors:  R Storb; H J Kolb; T C Graham; P J Kane; E D Thomas
Journal:  Transplantation       Date:  1972-08       Impact factor: 4.939

4.  The effect of prior transfusion on marrow grafts between histocompatible canine siblings.

Authors:  R Storb; R B Epstein; R H Rudolph; E D Thomas
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

5.  Failure of allogeneic canine marrow grafts after total-body irradiation. Allogeneic "resistance" versus transfusion-induced sensitization.

Authors:  R Storb; H J Deeg
Journal:  Transplantation       Date:  1986-12       Impact factor: 4.939

Review 6.  New strategies in the treatment of the thalassemias.

Authors:  Stanley L Schrier; Emanuele Angelucci
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

7.  Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors.

Authors:  H J Deeg; S Self; R Storb; K Doney; F R Appelbaum; R P Witherspoon; K M Sullivan; K Sheehan; J Sanders; E Mickelson
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

8.  Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.

Authors:  David A Jacobsohn; Reggie Duerst; William Tse; Morris Kletzel
Journal:  Lancet       Date:  2004 Jul 10-16       Impact factor: 79.321

9.  Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.

Authors:  W A Marijt; N A Kernan; T Diaz-Barrientos; W F Veenhof; R J O'Reilly; R Willemze; J H Falkenburg
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483

10.  Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor.

Authors:  R E Champlin; S D Nimer; P Ireland; D H Oette; D W Golde
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

View more
  2 in total

1.  Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sakura Hosoba; Edmund K Waller; Neeta Shenvi; Michael Graiser; Kirk A Easley; Zaid Al-Kadhimi; Akira Andoh; Ana G Antun; Sheliagh Barclay; Cassandra D Josephson; Jean L Koff; H Jean Khoury; Amelia A Langston; James C Zimring; John D Roback; Cynthia R Giver
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-04       Impact factor: 5.742

Review 2.  Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

Authors:  Seema R Patel; James C Zimring
Journal:  Transfus Med Rev       Date:  2013-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.